Global Gene Therapy Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Technique (Gene Augmentation, Gene Inhibition, Killing Of Specific Cells), By Vector Type (Viral Vectors, Non-Viral Vectors), By Indication (Genetic Disorders, Cardiovascular, Oncology, Others) And By Geography - Forecasts From 2019 To 2024

Published:  Nov 2022 Report Code: KSI061611924 Pages: 127

The global gene therapy market is expected to grow at a CAGR of 18.39% over the forecast period to reach US$11.769 billion by 2027 from US$3.611 million in 2020. Gene therapy refers to a medical process that modifies or teat an individual’s underlying genetic problem thereby preventing disease. Such therapy has high applicability in the treatment of major diseases such as cancer, diabetes, heart disease, and HIV among others as its ability to replace unhealthy genes with new ones provides the body with the ability to fight such diseases. Unhealthy food consumption, lifestyle factors, and the rising prevalence of obesity, coupled with the rapid increase in the population and economic downturn have increased the prevalence of chronic and infectious diseases such as cancer, diabetes, HIV, and heart disease. For instance, according to the World Health Organization, in 2020, the number of deaths that occurred due to cancer globally stood at 10 million with which death count by breast cancer stood at 2.26 million followed by lung cancer at 2.21 million. Furthermore, according to US Government’s HIV.gov data, in 2021, 1.2 million people in the United States were diagnosed with HIV. Moreover, according to the 2020 Health and Glance report by European Commission, in 2019, the total number of people diagnosed with diabetes stood at 32.3 million which showed significant growth of 92.2% from the cases reported in 2000. Owing to the rapidly growing prevalence of such major diseases, the demand for gene therapy products is also projected to increase, thereby boosting the global gene therapy market growth during the forecast period.

Based on vector type, the global gene therapy market is segmented into viral and non-viral vectors. The non-viral vector is expected to grow at a relatively higher rate during the forecast period of the global gene therapy market. Non-viral vector has low cost, is easy to produce, has better cell or tissue targeting, and provides biosafety advantages over viral vector which makes the non-viral vector much safer to be used in gene delivery. Owing to its rich performance benefits, the non-viral vector has a higher preference over the viral vector, and with the increase in the number of major communicable and non-communicable diseases such as cancer, diabetes, and AIDS, the demand for non-viral vectors for gene therapy is also expected to increase, thereby improving its segment as well as the overall market growth during the forecast period.

The growing establishment of gene therapy manufacturing plants by major companies is boosting the global gene therapy market growth. Various companies realizing the importance of gene therapy and its effectiveness against a wide range of deadly diseases are actively investing in innovations and plant establishments to increase their production of gene therapy products. For instance, in June 2022, REGEXBIO announced the establishment of its new gene therapy manufacturing center in Rockville, Md where the company will boost the manufacturing of its adeno-associated virus vectors using the company’s NAV technology. Furthermore, in December 2021, Pfizer opened its new state-of-the-art gene manufacturing facility in Durham, NC, where the company will boost the production of its multiple gene therapy medicine. Such manufacturing plant establishments will increase the demand and scope of usage of gene therapy in the future, thereby boosting the market growth of the global gene therapy market during the forecast period.

Recent development and expansion

  • In October 2022, Elli Lily and Company signed an agreement for the acquisition of Akouos for a sum of US$610 million. The acquisition will enable Elli Lily to add major gene therapy products of Akouos such as AK-OTOF which is used for treating hearing loss caused due to otoferlin gene mutations.
  • In August 2022, Cytiva collaborated with Forecyte Bio to accelerate the manufacturing and development of the gene therapy industry in the United State and China markets. The company’s collaboration will increase the patient’s access to gene therapy.
  • Thermo Fisher Scientific, in January 2022, acquired PeproTech for uS$1.85 billion which is one of the leading providers of recombinant proteins used in the development of gene therapies. The acquisition came as strategic by Thermo Fisher to combine its cell culture technologies with PeproTech’s recombinant proteins that will revolutionize the gene therapy products of the company.
  • In December 2021, Novartis entered into a strategic agreement to acquire UK-based gene therapy Gyroscope Therapeutics. The acquisition will enable Novartis to add the GT005 gene therapy product of Gyroscope to its portfolio, which is used for geographic atrophy.

Covid 19

The COVID-19 pandemic led to a global lockdown and restrictions implemented by the governing authorities led to a decrease in diagnostic and medical treatment of major diseases such as cancer, diabetes, and HIV all of which, gene therapy has high applicability. For instance, according to the data provided by HIV.gov which is US Federal government’s official site for HIV, in 2020, the number of people who received HIV diagnosis in the US stood at 30,635 which showed a decrease of 17% in comparison to the 2019’s diagnosis. Such a decrease in diagnostic treatment reduced the demand for gene therapy in major countries like the US, thereby negatively impacting the growth of the global gene therapy market. However, with the restriction being lifted, the market is expected to show steady growth during the forecast period.

Global Gene Therapy Market Scope:

Report Metric Details
 Market size value in 2018  US$3.425 billion
 Market size value in 2024  US$8.748 billion
 Growth Rate  CAGR of 16.92% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Technique, Vector Type, Indication, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered AveXis, Inc, Pfizer Inc., MeiraGTx Limited, Errant Gene Therapeutics, American Gene Technologies Inc., IVERIC bio, Inc., Lysogene, AVROBIO, Inc., Adverum Biotechnologies, Spark Therapeutics, Inc.
 Customization scope  Free report customization with purchase

 

Segmentation

  • By Therapy Type
    • Ex Vivo
    • In Vivo
    • In Situ
  • By Vector Type
    • Viral
    • Non-Viral
  • By Technique Type
    • Gene Augmentation
    • Gene Inhibition
    • Specific Cell Kill
  • By Disease Type
    • Cancer
    • Heart Disease
    • Diabetes
    • HIV
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • United Arab Emirates
      • Others
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Australia
      • Indonesia
      • Thailand
      • Taiwan
      •  
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the gene therapy market size by 2024?
A1. The gene therapy market is anticipated to reach a total market size of US$8.748 billion by 2024. 


Q2. What is the size of the global gene therapy market?
A2. Gene Therapy Market was valued at US$3.425 billion in 2018. 


Q3. What are the growth prospects for the gene therapy market?
A3. The global gene therapy market is anticipated to grow at a CAGR of 16.92% during the forecast period. 


Q4. Which region holds the largest market share in the gene therapy market?
A4. Geographically, North America is expected to hold a significant share in the gene therapy market owing to the prevalence of cancer in addition to the highest health expenditure of the United States among all the developed regions of the world. 


Q5. How is the global gene therapy market segmented?
A5. The gene therapy market has been segmented based on type, technique, vector type, indication, and geography.

1. INTRODUCTION

1.1. Market Overview

1.2. Covid-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

 

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Driver

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of End-Users

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. GLOBAL GENE THERAPY MARKET, BY THERAPY TYPE

5.1. Introduction

5.2. Ex Vivo

5.3. In Vivo

5.4. In Situ

 

6. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE

6.1. Introduction

6.2. Viral

6.3. Non-Viral

 

7. GLOBAL GENE MARKET, BY TECHNIQUE TYPE

7.1. Introduction

7.2. Gene Augmentation

7.3. Gene Inhibition

7.4. Specific Cell Kill

 

8. GLOBAL GENE THERAPY MARKET, BY DISEASE TYPE

8.1. Introduction

8.2. Cancer

8.3. Heart Disease

8.4. Diabetes

8.5. HIV 

8.6. Others

 

9. GLOBAL GENE THERAPY GOWNS MARKET, BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. USA

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. Germany

9.4.2. France

9.4.3. United Kingdom

9.4.4. Italy

9.4.5. Spain

9.4.6. Others

9.5. Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. Israel

9.5.3. United Arab Emirates

9.5.4. Others

9.6. Asia Pacific

9.6.1. China

9.6.2. Japan

9.6.3. South Korea

9.6.4. India

9.6.5. Australia

9.6.6. Indonesia

9.6.7. Thailand

9.6.8. Taiwan

9.6.9. Others

 

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

 

11. COMPANY PROFILES

11.1. Novartis

11.2. Pfizer Inc.

11.3. MeiraGTx Limited

11.4. San Rocco Therapeutics 

11.5. American Gene Technologies

11.6. IVERIC bio, Inc

11.7. Lysogene

11.8. AVROBIO Inc

11.9. Adverum Biotechnologies Inc

11.10. Sprak Therapeutics, Inc.

Novartis

Pfizer Inc

MeiraGTx Limited

San Rocco Therapeutics

American Gene Technologies

IVERIC bio, Inc

Lysogene

AVROBIO Inc

Adverum Biotechnologies Inc

 

Spark Therapeutics, Inc.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us